{"filing":{"accession_number":"0001654954-26-007677","cik":"0000901832","ticker":"AZN","company_name":"ASTRAZENECA PLC","form":"6-K","filing_date":"2026-08-17","report_date":"2026-08-17","primary_document":"a8441q.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/901832/000165495426007677/a8441q.htm"},"events":[{"id":28087,"run_id":25671,"accession_number":"0001654954-26-007677","anchor_item_number":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"This 6-K furnishes a press release announcing positive Phase III trial results (SAFFRON) for Tagrisso plus Orpathys in EGFRm lung cancer, showing statistically significant improvements in progression-free and overall survival. While technically a clinical trial result rather than financial earnings, this disclosure of material clinical efficacy data for a key oncology product would affect a reasonable investor's assessment of the registrant's pipeline and commercial prospects. The announcement emphasizes this as \"the first global Phase III trial to show significant progression-free and overall survival benefits in this setting,\" reinforcing its materiality to the company's oncology strategy.","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-08-17","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":29892,"accession_number":"0001654954-26-007677","item_number":null,"item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"This 6-K furnishes a press release announcing positive Phase III trial results (SAFFRON) for Tagrisso plus Orpathys in EGFRm lung cancer, showing statistically significant improvements in progression-free and overall survival. While technically a clinical trial result rather than financial earnings, this disclosure of material clinical efficacy data for a key oncology product would affect a reasonable investor's assessment of the registrant's pipeline and commercial prospects. The announcement emphasizes this as \"the first global Phase III trial to show significant progression-free and overall survival benefits in this setting,\" reinforcing its materiality to the company's oncology strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-17T11:57:01.710892+00:00","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-08-17"}]}